Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Thoracic Surgery ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The biology and management of non-small cell lung cancer.Nature. 2018; https://doi.org/10.1038/nature25183
- Cell-free DNA in cancer diagnosis and follow-up.in: Govindan R. Devarakonda S. Cancer genomics for the clinician. Demos Medical Publishing, New York2019: 115-126
- Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol. 2014; 32: 579-586
- Application of plasma genotyping technologies in non–small cell lung cancer: a practical review.J Thorac Oncol. 2017; 12: 1344-1356
- Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.ESMO Open. 2018; 3: e000398
- DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer Res. 2001; 61: 1659-1665
- The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells.Immunology. 2005; 115: 55-62
- Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA).Mol Diagn Ther. 2019; 23: 311-331
- Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.Cancer Discov. 2017; 7: 1394-1403
- Detection and surveillance of bladder cancer using urine tumor DNA.Cancer Discov. 2018; : 10https://doi.org/10.1158/2159-8290.CD-18-0825
- Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.Elife. 2018; 7: 1-27
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.Nat Commun. 2015; 6: 1-6
- Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology.Mol Cancer Ther. 2017; 16: 948-955
- Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA.Semin Radiat Oncol. 2015; 25: 305-312
- Application of cell-free DNA analysis to cancer treatment.N Engl J Med. 2018; 379: 1754-1765
- Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study.Gene. 2016; 590: 142-1488
- Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.Cell Death Dis. 2019; 10: 534
- Isolation and characterization of DNA from the plasma of cancer patients.Eur J Cancer Clin Oncol. 1987; 23: 707-712
- False-positive plasma genotyping due to clonal hematopoiesis.Clin Cancer Res. 2018; 24: 4437-4443
- Circulating cell free DNA: preanalytical considerations.Clin Chim Acta. 2013; https://doi.org/10.1016/j.cca.2013.05.022
- Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC.J Thorac Oncol. 2018; https://doi.org/10.1016/j.jtho.2018.05.030
- The effect of preservative and temperature on the analysis of circulating tumor DNA.Clin Cancer Res. 2017; 23: 2471-2477
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).Nucleic Acids Res. 1989; 17: 2503-2516
- Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Expert Rev Mol Diagn. 2017; https://doi.org/10.1080/14737159.2017.1288568
- Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy.Clin Cancer Res. 2015;
- Digital PCR.Genetics. 1999; 96: 9236-9241
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med. 2015; 7: 1-7
- Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer.J Clin Oncol. 2016; 34: 3375-3382
- Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care.JAMA Oncol. 2016; 2: 1014-1022
- FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing.PLoS One. 2012; 7: 1-8
- Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer.Clin Cancer Res. 2019; https://doi.org/10.1158/1078-0432.CCR-19-0624
- Early stage NSCLC: challenges to implementing ctDNA-based screening and MRD detection.Nat Rev Clin Oncol. 2018; https://doi.org/10.1038/s41571-018-0058-3
- Integrated digital error suppression for improved detection of circulating tumor DNA.Nat Biotechnol. 2016; 34: 547-555
- A high-throughput assay for quantitative measurement of PCR errors.Sci Rep. 2017; 7: 1-11
- Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Arch Pathol Lab Med. 2018; https://doi.org/10.5858/arpa.2017-0388-CP
- The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients.Clin Cancer Res. 2018; 24: 3528-3538
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature. 2017; 545: 446-451
- EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291.Lung Cancer. 2015; 90: 509-515
- Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1713137
- Integrating liquid biopsies into the management of cancer.Nat Rev Clin Oncol. 2017; https://doi.org/10.1038/nrclinonc.2017.14
Hasan MM, Patel J, Johnson I, et al. Tracking minimal residual disease in post-operative cell-free DNA using MSK-ACCESS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1387.
- Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cellfree DNA.PLoS One. 2018; https://doi.org/10.1371/journal.pone.0194630
- Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA.Clin Cancer Res. 2017; 545: 60-65
- A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers.J Natl Cancer Inst. 2019; 111: 575-583
- Genomic profiling of advanced non–small cell lung cancer in community settings: gaps and opportunities.Clin Lung Cancer. 2017; https://doi.org/10.1016/j.cllc.2017.04.004
- Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2017; 15: 504-535
- The quest to overcome resistance to EGFR-targeted therapies in cancer.Nat Med. 2013; https://doi.org/10.1038/nm.3388
- Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer.J Thorac Oncol. 2017; https://doi.org/10.1016/j.jtho.2017.04.003
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nat Med. 2018; https://doi.org/10.1038/s41591-018-0134-3
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.Lancet. 2016; https://doi.org/10.1016/S0140-6736(16)00587-0
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet. 2017; 389: 255-265
- Early assessment of lung cancer immunotherapy response via circulating tumor DNA.Clin Cancer Res. 2018; 24: 1872-1880
- Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know.Am J Roentgenol. 2010; 195: 281-289
- Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.BMC Cancer. 2016; https://doi.org/10.1186/s12885-016-2049-z
- Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.PLoS Biol. 2014; 12: 1-7
- Tracking the evolution of non–small-cell lung cancer.N Engl J Med. 2017; 376: 2109-2121
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Nat Med. 2015; 21: 560-562
- Direct detection of early-stage cancers using circulating tumor DNA.Sci Transl Med. 2017; 9: 1-12
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Nat Commun. 2016; 7: 1-14
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Sci Transl Med. 2016; 8: 1-10
- Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the circulating cancer genome atlas (CCGA) study.J Clin Oncol. 2018; 36: 12003
- Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.N Engl J Med. 2014; 371: 2477-2487
- Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371: 2488-2498
- Perspective: clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.Blood. 2018; 126: 9-17
- Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life.Am J Hum Genet. 2017; 101: 50-64
- Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.Blood. 2017; 130: 742-752
- Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.Nat Commun. 2016; 7: 12484
- Cell-free DNA: preanalytical variables.Clin Chim Acta. 2015;
- Fragment length of circulating tumor DNA.PLoS Genet. 2016; 12: 1-24
- High fragmentation characterizes tumour-derived circulating DNA.PLoS One. 2011; 6: e23418
- Enhanced detection of circulating tumor DNA by fragment size analysis.Sci Transl Med. 2018; 10: 1-14
- Cross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasma.Theranostics. 2017; 7: 1437-1446
- Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.J Thorac Dis. 2018; https://doi.org/10.21037/jtd.2018.04.09
- Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study.J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2017.77.0412
Krebs M, Dive C, Dean EJ, et al. TARGET trial: molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials. In: JCO ASCO meeting. Chicago, June 3–7, 2016. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS11614.
Article info
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
